Table 1.
Baseline characteristics of studied patients
| Characteristic | Total N = 117 |
F1 + F2† n = 37 (32%) |
F3 + F4† n = 80 (68%) |
|
|---|---|---|---|---|
| Age (years), mean (range) | 45 (32-65) | 41 (32-60) | 39 (44-65) | |
| Sex, n (%) | ||||
| Males | 91 (78) | 19 (51) | 72 (90) | |
| Females | 26 (22) | 18 (49) | 8 (10) | |
| BMI (kg/m2) | 27.8 ±4.9 | 22.6 ±3.6 | 21.1 ±3.1 | |
| HCV RNA PCR | 108.5 ±42.7 | 110.3 ±43.1 | 112.8 ±39.3 | |
| Previous treatment regimens, n (%) | ||||
| SOF + DCV | 90 (77) | 25 (68) | 65 (81) | |
| SOF + LED | 24 (21) | 12 (32) | 12 (15) | |
| SOF + SIM | 3 (3) | 0 (0) | 3 (4) | |
| Previous treatment response, n (%) | ||||
| Non-responders | 42 (36) | 9 (24) | 33 (41) | |
| Relapses | 75 (64) | 28 (76) | 47 (59) | |
| Platelet count, n (%) | ||||
| ≥ 150 × 109/l | 76 (65) | 28 (76) | 48 (60) | |
| ≤ 150 × 109/l | 41 (35) | 9 (24) | 32 (40) | |
| Elevated ALT, n (%) | 68 (58) | 19 (51) | 49 (61) | |
| Comorbid diseases, n (%) | ||||
| Diabetes mellitus | 22 (19) | 15 (41) | 7 (9) | |
| Hypertension | 11 (9) | 8 (22) | 3 (4) | |
| HCV related cryoglobulinemia | 2 (2) | 2 (5.4) | 0 (0) | |
Data are expressed as n (%); mean with range or standard deviation. SOF – sofosbuvir, DCV – daclatasvir, LED – ledipasvir, SIM – simeprevir
†Liver stiffness was determined by FibroScan: F1-F2 (7-9 kPa), F3 (9-12 kPa), F4 (> 12.5 kPa)